Gritstone showcases mass spec-based neoantigen discovery platform

Gritstone Oncology Inc. (NASDAQ:GRTS) unveiled the inner workings of its mass spectrometry-based neoantigen identification platform, EDGE, in a Nature Biotechnology study published Monday. Results from the paper suggest building a machine-learning algorithm based on human leukocyte antigen (HLA)-bound peptides identified

Read the full 401 word article

User Sign In